ClinicalTrials.gg
CompletedNCT01220063RSCAMPTOUpdated Oct 30, 2026Results posted

Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC

A Phase 2 interventional study of Radiation and Irinotecan in Metastatic Colorectal Cancer, sponsored by Institut Cancerologie de l'Ouest. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Institut Cancerologie de l'Ouest · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Oct 2007, registered Oct 2010).
Updated Oct 30, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.

Enrollment
89th of 182
47 · median 47
Started
2007
with 11 others
Phase 2
117 of 200
16 open now
Registered
112th of 200
by date

Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is the 89th largest by enrollment of the 182 interventional ones that give a count, is one of 12 that started in 2007, is one of 117 in phase 2, and was the 112th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies testing irinotecan in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • RSHF
  • Irinotecan
  • Colorectal Cancer
  • metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > or = 18 years
  • Social Insurance
  • Performance Index \<2
  • > 6 months
  • adenocarcinoma colorectal ( proven)
  • (inoperable or recurrent after surgery),
  • hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if the two bodies are metastatic). The largest diameter of the metastasis will \< ou = 6cm for the liver, \< or = 6 cm for the lung. If multiple metastases, the sum of their maximum diameter is 6cm \< ou = the liver, \< ou = 6 cm for the lung.
  • Lesion (s) measurable (s) and evaluable (s)
  • CT less than 3 weeks
  • Patients must have received at least one prior chemotherapy regimen containing 5FU

    • Patients may have received one or more including irinotecan.
  • \<1.5 x
  • and ALT \<5x ULN
  • neutrophils> 1.5x109 / L, > 100x109 / L, > 9 g / dL
  • TP, TCA Normal (only for patients treated with a permanent implant)
  • signed.

Exclusion criteria

Exclusion Criteria:

  • to the administration of irinotecan.
  • History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation.
  • History of other invasive cancer treated in a period of less than 5 years (basal cell carcinoma and non-invasive cervical excepted)
  • disease diffuse or more than three metastases in the liver and / or lung during the natural history of disease (excluding any patient is having a complete radiological response on several metastases although 1-3 residual after treatment ( s) medical (at)).
  • Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left pulmonary arteries and right and left.
  • Pregnancy or breastfeeding.

    - Lack of means or refusal to use effective for men or women of childbearing age.

  • Any other concomitant experimental treatment.
  • Any other concurrent anticancer therapy, immunotherapy or hormonal therapy.
  • Monitoring impossible because of psychological, sociological or because of geographical distance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Other
    Radiation + Irinotecan

    Irinotecan will be administered : \- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy Radiotherapy (RSHF) will be administered : * at D1, D3, D8 and D10 * 48 Gy, 12 Gy by fractions twice a week

    Radiation: Radiation · Drug: Irinotecan

Interventions

  • RadiationRadiation

    10 Gy for 4 times (total 40 Gy)

    Also known as: RSHF

  • 40 mg/m² : Day 1 and day 8

    Also known as: Campto

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response Rate of Irradiated Lesions

    The primary objective is to increase the tumor response rate following stereotactic radiotherapy delivered at a total dose of 48 Gy in 4 fractions over 2 weeks, administered concomitantly with irinotecan at 40 mg/m² (on the 1st and 3rd irradiation sessions). Tumor response of the irradiated site will be assessed according to RECIST criteria by an investigator review committee, based on thoracic or hepatic CT imaging. Objective response is defined as the percentage of patients achieving either a complete response (CR) or a partial response (PR).

    Time frame: 48 months

Secondary outcomes

  1. Progression-Free Survival at 1 Year

    Progression-free survival (PFS) is defined as the time from the start of treatment to the first occurrence of disease progression (local or distant) or death from any cause. Progression will be assessed according to RECIST criteria based CT imaging. The 1-year PFS rate corresponds to the percentage of patients alive without disease progression at 12 months after treatment initiation.

    Time frame: 1 year

07

Results

Posted Oct 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneRadiation + Irinotecan
Started47
Completed47
Not completed0

Outcome measures

PrimaryObjective Tumor Response Rate of Irradiated Lesions

The primary objective is to increase the tumor response rate following stereotactic radiotherapy delivered at a total dose of 48 Gy in 4 fractions over 2 weeks, administered concomitantly with irinotecan at 40 mg/m² (on the 1st and 3rd irradiation sessions). Tumor response of the irradiated site will be assessed according to RECIST criteria by an investigator review committee, based on thoracic or hepatic CT imaging. Objective response is defined as the percentage of patients achieving either a complete response (CR) or a partial response (PR).

Time frame:
48 months
Reported as:
Count of participants · Participants
Objective Tumor Response Rate of Irradiated Lesions
ParticipantsRadiation + Irinotecan
Objective Tumor Response Rate of Irradiated Lesions42
SecondaryProgression-Free Survival at 1 Year

Progression-free survival (PFS) is defined as the time from the start of treatment to the first occurrence of disease progression (local or distant) or death from any cause. Progression will be assessed according to RECIST criteria based CT imaging. The 1-year PFS rate corresponds to the percentage of patients alive without disease progression at 12 months after treatment initiation.

Time frame:
1 year
Reported as:
Count of participants · Participants
Progression-Free Survival at 1 Year
ParticipantsRadiation + Irinotecan
Progression-Free Survival at 1 Year18

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Radiation + Irinotecan2/47 (4.3%)7/47 (14.9%)39/47 (83%)
Most frequent serious events
Most frequent serious events
EventRadiation + Irinotecan
Budd-Chiari syndromeBlood and lymphatic system disorders1/47
Abdominal painGastrointestinal disorders1/47
DiarrhoeaGastrointestinal disorders1/47
JaundiceHepatobiliary disorders1/47
PneumothoraxRespiratory, thoracic and mediastinal disorders1/47
Septic shockInfections and infestations1/47
sepsisInfections and infestations1/47
Most frequent other events
Most frequent other events
EventRadiation + Irinotecan
DiarrhoeaGastrointestinal disorders17/47
astheniaGeneral disorders13/47
vomitingGastrointestinal disorders8/47
anorexiaGeneral disorders3/47
anxietyPsychiatric disorders3/47

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Radiation + Irinotecan
<=18 years0
Between 18 and 65 years21
>=65 years26
Sex: Female, Male
Sex: Female, Male(Participants)Radiation + Irinotecan
Female0
Male47
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Radiation + Irinotecan
Region of Enrollment
Region of Enrollment(participants)Radiation + Irinotecan
France47
08

Study locations

6 sites
  • Hôpital Saint André
    Bordeaux, 33075, France
  • Centre Oscar Lambret
    Lille, 59 000, France
  • Centre Léon Berard
    Lyon, 69 000, France
  • Centre hospitalier Lyon Sud
    Lyon, 69000, France
  • Hôpital la Source
    Orléans, 45100, France
  • Centre René Gauducheau
    Saint-Herblain, 44805, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Aug 2018, 130 months.

Results were first posted in Oct 2026, 8 years 2 months after primary completion.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's 130 months is above that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2010
First posted
Oct 13, 2010
StartActual
Oct 19, 2007
Primary completionActual
Aug 2018
CompletionActual
Aug 2018
Results first posted
Oct 30, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Centre René Gauducheau · Saint-Herblain, France
Show 1 removed
  • Centre René Gauducheau · Saint Herblain, France
Oct 30, 2026
Enrollment
48→47
Oct 30, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore tumor response accoording to recist criteriaNow Objective Tumor Response Rate of Irradiated LesionsTime frame: 5 years → 48 months
Oct 30, 2026
Documents
Secondary outcomes
1 added
What changed in the outcomes
  • AddedProgression-Free Survival at 1 YearTime frame: 1 year
Oct 30, 2026
Title
RSHF in Colorectal Cancer→Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Centre René Gauducheau · Saint-Herblain, France
    Show 1 removed
    • Centre René Gauducheau · Saint Herblain, France
    Enrollment 48→47
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore tumor response accoording to recist criteriaNow Objective Tumor Response Rate of Irradiated LesionsTime frame: 5 years → 48 months
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedProgression-Free Survival at 1 YearTime frame: 1 year
    Title RSHF in Colorectal Cancer→Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC
    + 4 other changes: verification date, arm descriptions, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01220063
Responsible party
Sponsor
First posted
Oct 13, 2010
Start date
Oct 19, 2007
Primary completion
Aug 2018
Completion
Aug 2018
Results posted
Oct 30, 2026
Last update
Oct 30, 2026

Study contacts

RIO EMMANUEL, MD
study director · INSTITUT DE CANCEROLOGIE DE L'OUEST

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan

Start the discussion